Nasus Pharma Ltd. (NSRX) on Monday announced positive top line results from its Phase 2 study of NS002, the company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis.
The study enrolled healthy adults with a history of allergic rhinitis. All participants received single and repeat doses of NS002 and intramuscular EpiPen, with and without a nasal allergic challenge.
NS002 demonstrated a significantly faster time to reach the critical 100 pg/mL epinephrine threshold compared with EpiPen, with a median time of 1.69 minutes versus 3.42 minutes. At five minutes, 88.4% of subjects receiving NS002 reached the threshold compared with 64.6% for EpiPen.
The drug candidate also showed a favorable safety profile, with no serious adverse events reported and a pharmacodynamic response comparable to EpiPen across all participants.
The company said it plans to initiate a pivotal study in the fourth quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.